Literature DB >> 29328536

Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation.

Yannick D Muller1, Nseir Ghaleb1, Samuel Rotman2, Julien Vionnet1, Matthieu Halfon1, Emmanuelle Catana1, Déla Golshayan1, Jean-Pierre Venetz1, Vincent Aubert3, Manuel Pascual1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29328536     DOI： 10.1111/tri.13111

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


× No keyword cloud information.
  4 in total

Review 1.  Xenotransplantation: A New Era.

Authors:  Amber N Carrier; Anjali Verma; Muhammad Mohiuddin; Manuel Pascual; Yannick D Muller; Alban Longchamp; Chandra Bhati; Leo H Buhler; Daniel G Maluf; Raphael P H Meier
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

2.  Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results.

Authors:  Alberto Mella; Ester Gallo; Maria Messina; Cristiana Caorsi; Antonio Amoroso; Paolo Gontero; Aldo Verri; Francesca Maletta; Antonella Barreca; Fabrizio Fop; Luigi Biancone
Journal:  World J Transplant       Date:  2018-09-10

Review 3.  Management of allergy transfer upon solid organ transplantation.

Authors:  Yannick D Muller; Julien Vionnet; Franziska Beyeler; Philippe Eigenmann; Jean-Christoph Caubet; Jean Villard; Thierry Berney; Kathrin Scherer; Francois Spertini; Michael P Fricker; Claudia Lang; Peter Schmid-Grendelmeier; Christian Benden; Pascale Roux Lombard; Vincent Aubert; Franz Immer; Manuel Pascual; Thomas Harr
Journal:  Am J Transplant       Date:  2019-10-19       Impact factor: 8.086

4.  Atopy as an independent predictor for long-term patient and graft survival after kidney transplantation.

Authors:  Raphaël Porret; Raphaël P H Meier; Josip Mikulic; Manuel Pascual; Vincent Aubert; Thomas Harr; Déla Golshayan; Yannick D Muller
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.